Hunter Perkins Capital Management’s Haemonetics HAE Stock Holding History

Hunter Perkins Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Buy	18,512 +3,648	+25%	+$234K	0.31%	67
2026 Q1	$838K	Sell	14,864 -1,295	-8%	-$84.3K	0.2%	86
2025 Q4	$1.29M	Sell	16,159 -1,605	-9%	-$108K	0.3%	67
2025 Q3	$866K	Buy	17,764 +10,664	+150%	+$660K	0.19%	87
2025 Q2	$530K	Buy	+7,100	New	+$470K	0.13%	93

Other funds holding HAE

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Hunter Perkins Capital Management's HAE Position: Q2 2026 in Review

Hunter Perkins Capital Management increased its Haemonetics (HAE) stake by 25% in Q2 2026, buying an estimated $234K and bringing the position to 18,512 shares worth $1.39M. The position accounts for 0.31% of the portfolio, ranked #67.

Hunter Perkins Capital Management first reported a position in HAE in Q2 2025 and has held it in 5 quarters since. 31 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Hunter Perkins Capital Management held 18,512 shares of Haemonetics worth $1.39M as of Q2 2026.
Hunter Perkins Capital Management bought 3,648 Haemonetics shares in Q2 2026, an estimated $234K.
Haemonetics made up 0.31% of Hunter Perkins Capital Management's portfolio in Q2 2026, its #67 holding.
Hunter Perkins Capital Management first reported a position in Haemonetics in Q2 2025 and has held it in 5 quarters since.
31 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Hunter Perkins Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.